title: Different Radioiodine Dose for Remnant Thyroid Ablation in Patients With Differentiated Thyroid Cancer: A Meta-analysis.
abstract: OBJECTIVE
  Remnant thyroid ablation is crucial in the management of patients with differentiated thyroid cancer. However, the optimal dose of radioactive I for ablation is still controversial. This study aimed to compare the success rate of different activities of I for postoperative remnant ablation in randomized controlled trials (RCTs) and to determine the optimal dose.
  
  
  METHODS
  Sources were retrieved from the Cochrane Library, Medline, Embase, Scopus, and Google Scholar until March 2014. All RCTs that assessed the efficacy of different doses of I for ablation were selected. After data extraction, statistics were performed by Review Manager 5.2 software.
  
  
  RESULTS
  Seventeen RCTs were considered eligible, involving 3737 patients. The overall methodological quality of the studies was good. The rate of successful remnant ablation of low versus moderate I activities (risk ratio [RR], 0.89; 95% confidence interval [CI], 0.80-1.00; P = 0.06) and moderate versus high I activities (RR, 0.94; 95% CI, 0.89-1.00; P = 0.05) showed no significant differences. However, high I activities had 11% higher successful ablation rate than low activities with an RR of 0.89 (95% CI, 0.81-0.97; P = 0.008), which was significant.
  
  
  CONCLUSIONS
  We summarized all available randomized evidence to demonstrate that high dose of I was significantly better than low dose to achieve successful remnant thyroid ablation.
authors.affiliation: From the *Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin; †Department of Nuclear Medicine, Second Affiliated Hospital of Zhejiang Medical University, Hangzhou; ‡Department of Oncology, Tianjin Medical University General Hospital; and §Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenviroment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
authors.forename: Xinghua
authors.initials: X
authors.lastname: Song
authors.forename: Zhaowei
authors.initials: Z
authors.lastname: Meng
authors.forename: Qiang
authors.initials: Q
authors.lastname: Jia
authors.forename: Linlin
authors.initials: L
authors.lastname: Zhang
authors.forename: Ke
authors.initials: K
authors.lastname: Xu
authors.forename: Jian
authors.initials: J
authors.lastname: Tan
authors.forename: Guizhi
authors.initials: G
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Zheng
authors.forename: Xue
authors.initials: X
authors.lastname: Li
authors.forename: Jianping
authors.initials: J
authors.lastname: Zhang
mesh_terms: D000230:Adenocarcinoma / Q000601:surgery*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D011829:Radiation Dosage; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods*; D013964:Thyroid Neoplasms / Q000601:surgery*
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals